MedPath

To evaluate macular and peripapillary microvascular changes in systemic hypertension as measured by optical coherence tomography angiography technology

Not yet recruiting
Conditions
Background retinopathy and retinalvascular changes,
Registration Number
CTRI/2022/04/041654
Lead Sponsor
Department of Ophthalmology
Brief Summary

This study aims at evaluating changes occurring in the microvasculature of the retina primarily evaluated at the macular and peripapillary region through oct angiography in hypertensive patients in comparison to the normal control group. The study aims at picking up subtle signs of microvascular damage as measured by oct and octa technology well before clinical signs of hypertension manifest in the body.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

1.Hypertensive patients on medication for more than 5 years 2.Age: 30-60 years 3.BCVA ≥ 6/12.

Exclusion Criteria
  • 1.Significant ocular media opacity (in order to maximize good quality images) 2.Grade 3 hypertensive retinopathy and above (according to Keith Wagener Barker classification).
  • 3.Any other ocular pathology, e.g. macular edema, diabetic retinopathy, optic nerve disorders etc.
  • 4.Any intraocular surgery 5.Any other systemic illness.
  • 6.Refractive errors (> +3 D, axial length (AL) >26.0 mm).

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1-To measure Macular and peripapillary OCTA parameters (VD, PD and FAZ dimensions) in systemic hypertension vs control group.Baseline
Secondary Outcome Measures
NameTimeMethod
1) Measurement of structural OCT Parameters (CMT, GC-IPL and RNFL thicknesses)in systemic hypertension vs normal control group.

Trial Locations

Locations (1)

Guru Nanak Eye Centre

🇮🇳

Delhi, DELHI, India

Guru Nanak Eye Centre
🇮🇳Delhi, DELHI, India
Dr Yashi Gupta
Principal investigator
9873976836
yaasshi12@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.